29th Conference on Retroviruses on Opportunistic Infections (CROI 2022): First reports
1 March 2022. Related: Conference reports, Conference index, CROI 29 (Retrovirus) 2022.
Simon Collins, HIV i-Base
The 29th Conference on Retroviruses and Opportunistic Infections (CROI), was held from 13–16 and 22–24 February 2022.
The conference programme is now online as open access.
Although abstracts are online, webcasts will only be initially available to registered delegates for 30 days after the meeting.
A PDF file of the full programme is also now online:
Other conference material including searchable abstracts, webcasts and posters are expected to become open access four weeks after the meeting ends.
i-Base will post links to early reports from this holding page.
First reports from CROI 2022
- Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
- Injectable CAB/RPV-LA: phase 3b ATLAS-2M results at three years
- Lenacapavir: 6-monthly dosing in treatment-experienced participants and as PrEP in macaques
- Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
- Islatravir studies for HIV treatment and PrEP
- Fourth potential stem cell HIV cure – in a US woman using donor cord cells
- Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs
- Targetting reservoir with ART + bNAb 3BNC117 + romidepsin maintained undetectable viral load off-ART for 3.7 years in one case
- Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
- No impact of high-dose vitamin D3 on reducing the HIV viral reservoir
COMPLICATIONS, including COVID-19
- Risk factors for NAFLD and proteinuria in HIV positive people on ART
- Higher maternal mortality and adverse birth outcomes among women with COVID-19 in Botswana
- ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV
- Other studies on anal cancer
- Telomere shortening associated with TAF but not TDF in CHARTER study
- CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
- Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study
Page first posted on 7 February 2022, updated with new studies.